Phase 4 Asthma Trial, Recruiting NCT07166939 Sponsor: Massachusetts General Hospital Condition: Asthma
Back to Asthma

Phase 4 Asthma Trial, Recruiting

NCT07166939
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are having an acute (sudden) asthma attack
  • You are between 18 and 54 years old
  • You speak English and/or Spanish
  • The emergency department doctor has decided you can go home with a short course of steroid pills or liquid
  • You are willing to use a specific rescue inhaler called Airsupra for the next 3 months (required only if you are placed in the treatment group)
  • You are able to use a metered-dose inhaler (a standard puffer inhaler) correctly
  • You are willing and able to give your informed consent before any study procedures begin

Who may not be able to join:

  • You have been involved in planning or running this study
  • You have already taken part in this same study before
  • You have previously been diagnosed with COPD, chronic bronchitis, or emphysema (other lung conditions)
  • You have taken steroid medicines (such as prednisone) in the past 2 weeks
  • You are currently in another clinical trial involving an experimental treatment, or you were in one within the past 4 weeks, or plan to join one within the next 3 months
  • You currently have pneumonia at the same time as your asthma attack
  • You have a serious heart condition or serious cancer
  • You have a known allergy or sensitivity to Airsupra, albuterol sulfate, budesonide, or any ingredients in this product
  • You are currently pregnant (for women, by self-report)
  • You are currently breastfeeding (for women, by self-report)
  • You are a sexually active woman of childbearing age who has not been using adequate birth control in the last 3 months and does not plan to use it in the next 3 months
  • You do not have a working mobile phone and a working email address
  • You do not expect to be available for follow-up contact (by text or phone) at roughly 3, 6, and 12 weeks after your emergency department visit
  • You are unable to provide the details of an alternative contact person who has a working mobile phone and email address

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
7 November 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

acute asthma recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov